Elevai Labs Inc. (ELAB) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Elevai Labs Inc. (ELAB) effectively delegates the packaging and release of serums to reliable partners, ensuring process stability. High component purity is achieved through the implementation of robotic cleaning systems. Market fluctuations in the share price demonstrate the significance of 0.00, while the business relies on external contractors to scale the bottling of exosome cosmetics, maintaining a dependency on vendor stability.

Elevai Skincare - ELAB Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/12/2026)

ELAB (elevaiskincare.com): analytical breakdowns and indicator data

- market price and analyst price targets:

Price Chart Elevai Skincare|ELAB - Analyst Median Target

- market capitalization details:

Market Value Elevai Corp|ELAB - Enterprise Value

- book value of equity indicators:

Book Value per Share Elevai Labs|ELAB - Book Valuation of Business|Market Value to Book Value Ratio elevaiskincare.com|ELAB - Total Business Assets

- issuer credit burden and liquidity indicators:

- financial results and valuation multiples details:

ELAB - Net Profit|Projected Future Earnings Elevai Labs Inc.|ELAB - Business Payback Period|Projected Price to Earnings Elevai Labs Inc.|ELAB - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Elevai Corp|ELAB - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Elevai Labs|ELAB - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth elevaiskincare.com|ELAB - Earnings per share growth in current year|Net earnings per share growth forecast for next year Elevai Labs Inc.

Summary company analytics:Elevai Skincare ELAB

Investing in the high-tech sector requires a precise analysis of business value relative to operating profit. The EV/EBITDA ratio of the company on the financial timeline reflects the relationship between the total enterprise value, including debt, and earnings before interest, taxes, depreciation, and amortization, taking the value 0.00. For Elevai Labs Inc. (ELAB), which is setting standards for exosome-based regenerative cosmetics, this metric confirms the effective capitalization of molecular innovations.

Competitor analysis

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Krystal Corp KRYS|Total Company Value to Operating Income Before Depreciation Ratio Apogee Corp (APGE)|ARQT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VCEL - EV/EBITDA Multiple|ORKA: EV/EBITDA Multiple|SMTI - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization DBV Tech|Enterprise Value to Operating Income Before Depreciation SLSN (Solesence Inc.)|EV/EBITDA Multiple DERM|FBRX - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Empro Group EMPG|Sol-Gel Technologies Ltd - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Revive Pro Care - EV/EBITDA Multiple|Company Value to EBITDA Medicus Pharma Corp|VRCA (verrica.com) - Enterprise Value to EBITDA Ratio|HOTH (Hoth Therapeutics) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BFRI (Biofrontera, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple VYNE Therapeutics Inc|EV/EBITDA Multiple SNOA|Total Company Value to Operating Income Before Depreciation Ratio quoinpharma.com|Azitra, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation DRMA|RVNC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization